Clinical AI Solutions

Artemis™ is a precision intelligence platform engineered to solve the "data scarcity" problem in pediatric oncology. By leveraging advanced AI architectures, it transforms fragmented, global research into actionable clinical insights.

Artemis™ operates as a sophisticated analytical layer that sits atop existing medical data infrastructures to accelerate the path to a cure.

• Federated Data Synthesis: It utilizes Federated Learning to analyze sensitive patient data across multiple international institutions simultaneously. This allows the AI to "learn" from a global pool of rare cancer cases without the raw data ever leaving its secure home facility.
• Multi-Omic Pattern Recognition: The platform integrates diverse biological datasets—including genomics, proteomics, and transcriptomics—to create a high-definition molecular map of pediatric tumors.
• Predictive Outcomes Modeling: Artemis™ calculates the Probability of Progression ($P_p$) and treatment response by identifying "molecular twins" across historical data, helping clinicians move beyond "one-size-fits-all" protocols.
• Precision Trial Matching: It autonomously scans global clinical trial registries to match pediatric patients with experimental therapies based on their specific genetic drivers, significantly reducing the time from diagnosis to enrollment.

Artemis™ is designed for the high-level stakeholders driving the future of precision medicine.

• Pediatric Oncologists & Clinicians: Provides a "super-powered" second opinion at the bedside, offering data-backed insights into rare mutations and targeted therapy options.
• Research Institutions & Bioinformaticians: Serves as a force-multiplier for discovery, allowing researchers to find patterns in "small N" (rare) datasets that were previously statistically invisible.
• Federal Agencies (NIH/NCI): Acts as the critical infrastructure for national initiatives (like the CCDI) to harmonize data and meet federal mandates for AI-driven healthcare innovation.
• Strategic Payors & CMS: Enables a shift toward Value-Based Care by predicting which high-cost therapies are most likely to be effective, thereby reducing waste and improving long-term survivorship metrics.
• Biopharmaceutical Developers: Accelerates the R&D pipeline for pediatric-specific orphan drugs by identifying viable patient cohorts for specialized clinical trials.

Reimagining Animal Testing with Agentic AI Models for Cancer Drug Discovery 

ONCOSIM-AI is an integrated, six-layer artificial intelligence framework designed to revolutionize the way cancer treatments are developed.

The system replaces the traditional, often inaccurate animal testing phase with a sequence of high-fidelity computational models.

• End-to-End Drug Discovery: It manages the entire preclinical pipeline, from identifying genetic cancer targets (Layer 1) to predicting how a specific patient will respond to a drug (Layer 6).
  
• Biological Simulation: It uses Graph Neural Networks and AlphaFold2 to predict protein structures and drug-target interactions, replacing physical tissue assays.
  
• Digital Twins: It creates patient-specific computational tumor models from biopsy genomics to simulate real-world treatment outcomes without the need for mouse models.
  
• Performance Optimization: The framework aims to reduce drug development timelines from 15 years down to 3–5 years while cutting costs by up to 80%.
  

ONCOSIM-AI is built for stakeholders across the healthcare and biotechnology sectors who are looking to move toward more ethical and accurate research methods.

• Pharmaceutical Companies: Organizations like AstraZeneca, Novartis, and Pfizer that are committed to reducing animal use and lowering the $2.6 billion average cost of bringing a drug to market.
  
• Regulatory Bodies (FDA & EMA): The system is designed to align with new standards like the US FDA Modernization Act 2.0, which allows for non-animal testing data in human trial submissions.
  
• Precision Oncology Clinics: Medical professionals who require personalized "Digital Twin" models to determine the most effective treatment for an individual patient's unique genetic profile.
  
• Academic & Research Institutions: Researchers focusing on ethical AI, computational biology, and the elimination of animal experimentation.